Neurostimulation devices are utilized to restore function and re-normalize the circuiting of the nervous system in neurological conditions such as drug-refractory epilepsy, major depressive disorder, post-stroke extremity dysfunction, as well as Alzheimer’s and Parkinson’s disease. Globally, neurological conditions affect hundreds of millions of people.
Neurostimulation Technologies for Targeted Neurological Conditions – Summary
|
2019 Market Size |
$1.5B |
|
Types of Technologies |
Invasive and Noninvasive Products |
|
Product Types |
Deep Brain Stimulation; Vagus Nerve Stimulation; Transcranial Magnetic Stimulation |
|
Market Leaders |
Abbott, Boston Scientific, LivaNova, Medtronic |
|
Other Competitors |
Neuronetics, Ottobock, PINS Medical, others |
New Market Report Forecasts Rapid Growth
According to a new report from LSI’s Medtech Pro market intelligence platform, global sales of neurostimulation devices for the treatment of targeted neurologic conditions are estimated to total $1.5bn in 2019. During the forecast period covered by this analysis, sales attributable to neurostimulation devices will increase at a compound annual growth rate (CAGR) of 12.7%, reaching $2.8bn by 2024. Deep brain stimulation (DBS) are implanted to relieve patients of neurological conditions such as Alzheimer’s disease, Parkinson’s disease, and essential tremor. Sales attributable to DBS devices were estimated to account for the majority (~55%) of global neurostimulation sales in 2019. Implantable neurostimulation devices accounted for nearly 90% of global neurostimulation technology sales in 2018.
By geography, the US is the largest market in terms of total neurostimulation device sales and will continue to account for the greatest share of total device sales throughout the forecast period covered by this analysis. HRI estimates that the US accounted for over 75% of global sales in 2019 – a trend that is projected to persist throughout the forecast.
Competitive Landscape
Market leaders in the neurostimulation devices market include Abbott, Boston Scientific, LivaNova and Medtronic. Together these companies accounted for over 80% of global neurostimulation device sales in 2018. Other competitors offering neurostimulation devices for the treatment of targeted neurological conditions covered by this report include Neuronetics, Ottobock, and PINS Medical, among others.
Visit Life Science Intelligence (LSI) to learn more about how neurostimulation technologies are transforming the management and treatment of some of the most debilitating forms of neurological disease.
Emerging Companies, Investors & Strategic Buyers
A select group of innovative early stage companies developing new technologies in this rapidly growing market will be presenting to an audience of venture capitalists and strategic buyers at LSI's annual Emerging Medtech Summit.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
